Medicare Enrolled

Dr. Marc Bowen, M.D.

Pulmonary Disease · New York, NY
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
209 W 19TH ST, New York, NY 10011
2124804062
In practice since 2006 (20 years)
NPI: 1205815032 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bowen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bowen? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Bowen

Dr. Marc Bowen is a pulmonary disease specialist in New York, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Bowen performed 840 Medicare services across 394 unique beneficiaries.

Between the years covered by Open Payments, Dr. Bowen received a total of $7,955 from 27 pharmaceutical and/or device companies across 195 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Bowen is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 46% volume in NY $7,955 industry payments

Medicare Practice Summary

Medicare Utilization ↗
840
Medicare services
Top 46% in NY for pulmonary disease
394
Unique beneficiaries
$180
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~42 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Critical care, first 30-74 min
Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient.
 699 $197 $1,288
Additional 30 minutes of critical care
This code represents an additional 30 minutes of critical care services provided beyond the initial critical care time period.
 70 $99 $578
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
 40 $80 $168
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
 31 $109 $493
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$7,955
Total received (2018-2024)
Avg $1,136/year across 7 years
Top 22% in NY for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
27
Companies
195
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,955 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,804
2023
$259
2022
$567
2021
$744
2020
$987
2019
$1,773
2018
$1,821

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,077
GlaxoSmithKline, LLC.
$354
kaleo, Inc.
$108
CSL Behring
$82
Pharming Healthcare, Inc.
$52
Regeneron Healthcare Solutions, Inc.
$50
Blueprint Medicines Corporation
$32
Genentech USA, Inc.
$26
Takeda Pharmaceuticals U.S.A., Inc.
$23
Top 3 companies account for 85.3% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$2,631
GlaxoSmithKline, LLC.
$1,724
Genentech USA, Inc.
$1,556
PFIZER INC.
$293
Inari Medical, Inc.
$228
Regeneron Healthcare Solutions, Inc.
$217
GENZYME CORPORATION
$196
Mylan Specialty L.P.
$160
kaleo, Inc.
$127
CSL Behring
$106
Boehringer Ingelheim Pharmaceuticals, Inc.
$98
Pharming Healthcare, Inc.
$70
Melinta Therapeutics, LLC
$63
Philips Electronics North America Corporation
$62
Insmed, Inc.
$59
OptiNose US, Inc.
$49
SANOFI-AVENTIS U.S. LLC
$45
Mallinckrodt Hospital Products Inc.
$41
Teva Pharmaceuticals USA, Inc.
$40
Circassia Pharmaceuticals Inc
$36
Blueprint Medicines Corporation
$32
Takeda Pharmaceuticals U.S.A., Inc.
$23
Grifols USA, LLC
$22
Janssen Pharmaceuticals, Inc
$22
Amgen Inc.
$20
Novartis Pharmaceuticals Corporation
$19
Optinose US, Inc.
$17
Top 3 companies account for 74.3% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AIRSUPRA · AJOVY · ANORO · ANORO ELLIPTA · AUVI-Q · AYVAKIT · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · CHANTIX · CUVITRU · DUAKLIR PRESSAIR · DUPIXENT · Dymista · ELIQUIS · EUCRISA · Esbriet · FASENRA · FLOWTRIEVER CATHETER · Haegarda · Hizentra · Kcentra · Kimyrsa · NIOX VERO · NUCALA · OFEV · Perforomist · Prolastin-C Liquid · RUCONEST · S · STIOLTO · SYMBICORT · TEZSPIRE · TRELEGY ELLIPTA · Wellcentive Undiv · XARELTO · XOLAIR · Xhance · Xolair · Yupelri
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a pulmonary disease specialist in New York?
Compare pulmonary diseases in the New York area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases within 10 mi
657
Per 100K population
40.4
County median income
$104,553
Nearest hospital
NY EYE AND EAR INFIRMARY OF MOUNT SINAI
0.9 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Bowen is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Bowen experienced with critical care, first 30-74 min?
Based on Medicare claims data, Dr. Bowen performed 699 critical care, first 30-74 min services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bowen receive payments from pharmaceutical companies?
Yes. Dr. Bowen received a total of $7,955 from 27 companies across 195 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bowen's costs compare to other pulmonary diseases in New York?
Dr. Bowen's average Medicare payment per service is $180. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bowen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in New York
Browse pulmonary diseases in New York ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NY
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NY
Which NY pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →